Learn how the successful development of combination products will require great collaboration within the industry to overcome regulatory, clinical, and technical challenges.
Combination products are emerging as innovative medical products due to their contribution to advancing medical care and are expected to have major impact in the coming years. Future technologies are most appealing to patients with ongoing medical conditions that require consistent treatment with daily injections or weekly procedures and unmet medical needs. Overall, the successful development of combination products will require great collaboration within the industry to overcome regulatory, clinical, and technical challenges.
With the rapidly aging baby-boomer population, the pressure for companies to create safer and more effective treatments is growing. Combination products are one of the solutions that have emerged to meet the more rigorous demands of patients. Drug-enhanced devices, including drug eluting stents and antimicrobial-coated catheters, have already proven themselves on the market. Pre-filled syringes and transdermal patches, which are novel drug delivery systems, have also been widely used in treatments. However, the combination products that are some of the most innovative are regenerative medicine products. These types of products can provide cures for previously untreatable conditions, which can truly change the face of the industry.
In this webinar, you will learn through case studies and a panel discussion how to navigate the future regulatory framework for unmet medical needs and next generation of drug delivery devices. Discover how it will lead to the industry developing emerging and disruptive combination products for use within the umbrella of precision medicine. Technology innovations driving precision medicine include community-wide genetic screening and early disease detection and risk management, preventative health strategies, digital health strategies, wellness programs will also be discussed.
Upon completion of this workshop, participants will be able to:
Intermediate: Content is designed based upon the assumption that individuals have basic knowledge of the topic(s) and/or demonstrated competence related to the topic(s). Higher-level concepts are introduced during lectures; exercises requiring synthesis and/or application of concepts are incorporated into the activity.
Mid-senior level quality assurance and regulatory affairs professionals who are involved with the development and commercialization of complex devices and combination products.
| Time | Topic |
|---|---|
| 10:00 AM |
Overview of Integrated Regulatory Strategy:
|
| 10:45 AM | Interactive Workshop: Strategic Partnership Development and CDMO Engagement |
| 11:30 AM |
Break |
| 11:40 AM |
Deep Dive: Leveraging Target Product Profiles (TPPs) to Enhance Regulatory Pathways for Complex Devices and Combination Products |
| 11:55 AM | Hands-on Workshop: Optimal Integration and Utilization of TPPs for Device Development |
| 12:40 PM | Consolidation and Discussion of Key Insights |
| 1:00 PM | Course Adjourned |
RAPS reserves the right to cancel this program at its sole discretion. RAPS will not be responsible for travel or other costs incurred due to cancellation. All cancellation requests must be submitted in writing to [email protected]. Cancellations will receive a full refund minus a 20% administrative fee. RAPS is unable to accept cancellations by phone.
Paid registration substitutions may be accepted with written approval from RAPS for requests received before the start of the event. To transfer a registration, email [email protected] with the event title, name of the original registrant and the contact information for the new attendee.
A certificate of attendance can be downloaded from the RAPS Learning Portal following the event.
Contact the RAPS Support Center:
Call +1 301 770 2920, ext. 200 (8:30 am–5:30 pm EST, Monday–Friday) or email [email protected].

Head, Global Regulatory Affairs - Emerging Tech and Combination Products, AbbVie



Head, Global Regulatory Affairs - Emerging Tech and Combination Products, AbbVie
James Wabby has 23 years of experience in increasing regulatory compliance and regulatory affairs responsibilities within the GxP regulated environment pertaining to medical devices, medicinal delivery platforms, companion diagnostics, digital medicine, and combination product areas. He regularly provides AbbVie therapeutic franchise units with regulatory counsel and strategy to all aspects within the quality management system and regulatory affairs. James is an internationally recognized leader as he is a member of various regulatory/quality work groups and is a speaker and keynote at various regulatory symposia. In addition, he is the chair of the RAPS -LNG Southern California, vice chair RAPS RCC Committee, chair of the DIA Combination Products Committee, chair of the ISPE Combination Products (CoP), and a moderator for various global regulatory panel discussions.
Vice President of Regulatory and Quality Services, EdgeOne Medical
Jerzy Wojcik has more than 26 years of experience guiding medical device and drug–device combination product programs through global development, clinical readiness, regulatory approval, and lifecycle management. He is recognized for translating complex global regulatory and quality requirements into executable development and commercialization strategies that support product approval and sustained compliance.
Throughout his career, Jerzy has led global regulatory strategy and quality system implementation across diverse markets. He has directed and authored complex device regulatory submissions, including 510(k), PMA, EUA, and IDE applications, as well as EU Technical Files. In addition, he has overseen and prepared eCTD-format drug submissions for IND, BLA, NDA, and MAA applications, ensuring compliance with applicable regulatory requirements and agency expectations. He has supported high-risk and novel technologies ranging from implantable devices to combination products and biologics.
Prior to EdgeOne Medical, he held global regulatory leadership roles at Baxter Healthcare and Avery Dennison, and earlier in his career he worked in regulatory risk consulting at Deloitte. Jerzy also provides regulatory and quality due diligence for venture capital firms and innovation hubs evaluating early- and growth-stage medical technology companies. He has served as a retained expert witness in U.S. federal court proceedings involving medical device development activities.

VP, Solutions Engineering, Suttons Creek
Carolyn Dorgan is an influential leader with 15+ years of experience spanning the FDA, medical device, biologics, and combination product industries. As vice president of Solutions Engineering at Suttons Creek, she guides clients through complex regulatory, quality, and organizational challenges in combination product development, driving alignment and action across diverse functions and cultures.
Previously, Carolyn held leadership roles at the U.S. FDA, leading the Infusion Devices team and shaping international standards for drug delivery, injection systems, and pediatric medical devices. She is a recognized voice in combination product development, contributing to over a dozen standards and guidance documents. Carolyn holds a BS in Biomedical Engineering (University of Minnesota), an MS in Technology Commercialization (University of Texas), and executive leadership training from The Wharton School.
We have completed our migration to a new platform and are pleased to introduce the updated site.
What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.
We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.
We welcome your feedback. Please let us know how we can continue to improve your experience.